Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles

Clin Transl Sci. 2016 Feb;9(1):9-22. doi: 10.1111/cts.12386. Epub 2016 Feb 5.

Authors

K Venkatakrishnan¹, C Burgess¹, N Gupta¹, A Suri¹, T Takubo², X Zhou¹, D DeMuria¹, M Lehnert¹, K Takeyama², S Singhvi¹, A Milton¹

Affiliations

¹ Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts, USA.
² Takeda Pharmaceutical Company Limited, Tokyo, Japan.

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antineoplastic Agents / pharmacokinetics
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Asia
Dose-Response Relationship, Drug
Health Services Accessibility*
Humans
Neoplasms / drug therapy*
Practice Guidelines as Topic*
Risk Assessment*

Substances

Antineoplastic Agents